Latin America Ploughs Ahead With Joint Pricing Strategy
This article was originally published in Scrip
Pharmaceutical companies wanting to sell high-cost drugs in Latin America may find themselves talking with multiple countries at once to find a single acceptable price. Mercosur member and associate countries are wielding their collective might to secure lower prices through a new negotiation mechanism supported by the Pan American Health Organization / World Health Organization. Mercosur health ministers have already announced an offer from Gilead to supply its hepatitis C drug Sovaldi (sofosbuvir) and next up for discussion are likely to be costly cancer medicines.
You may also be interested in...
Latin American joint price negotiations have proved successful and other countries are taking note.
A South American pricing coalition that includes Brazil, Venezuela and Argentina has announced plans to buy high-cost drugs, such as eculizumab (Alexion’s Soliris).
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.